Table 2.
Changes in clinical outcomes and medications during follow-up of the whole group of patients.
| Visit 1 n = Frequency Median (IQR) |
Visit 2 n = Frequency Median (IQR) |
Visit 3 n = Frequency Median (IQR) |
p Value * | |
|---|---|---|---|---|
| VAS pain |
n = 215 4 (2–6) |
n = 201 4 (2–6) |
n = 167 4 (2–6) |
0.8382 |
| PGA | 3 (2–5) | 3(2–5) | 3 (2–4) | 0.349 |
| PAS |
n = 215 3 (1.3–4.4) |
n = 201 2.7 (1.4–4.1) |
n = 168 2.7 (1.8–3.8) |
0.8382 |
| DAS28 |
n = 109 2.6 (2.1–3.6) |
n = 35 2.7 (2.4–3.5) |
n = 60 2.7 (2.2–3.5) |
0.7115 |
| HAQ |
n = 216 0.07 (0–0.9) |
n = 201 0.1 (0–0.6) |
n = 175 0.1 (0–0.6) |
0.1694 |
| EQ5-VAS |
n = 217 70 (50–80) |
n = 206 70 (60–80) |
0.1153 | |
| EQ5-overall index | 0.7 (0.5–0.8) | 0.7 (0.5–0.8) | 0.4294 | |
| EQ5-TTO | 0.7 (0.6–0.9) | 0.7 (0.6–0.9) | 0.411 | |
| ASAS-R |
n = 218 65 (61–68) |
n = 206 69 (64–77) |
0.0001 | |
| MORISKY | Visit 1 n = 218 (%) |
Visit 3 n = 206 (%) |
p value * | |
| Adherence | 140 (64.2) | 117 (56.8) | 0.118 | |
| Non-adherence | 78 (35.8) | 89 (43.2) | ||
| Medications | ||||
| Visit 1 n = 218 |
Visit 2 n = 201 |
Visit 3 n = 206 |
p Value * | |
| Analgesics | n (%) | n (%) | n (%) | |
| Acetaminophen | 151 (69.3) | 134 (66.7) | 122 (59.2) | 0.081 |
| Codeine | 7 (3.2) | 9 (4.5) | 12 (5.8) | 0.429 |
| Hydrocodone | 30 (13.8) | 26 (12.9) | 23 (11.2) | 0.715 |
| Oxycodone | 1 (0.5) | 1 (0.5) | 1 (0.5) | 1.00 |
| Tramadol | 15 (6.9) | 9 (4.5) | 9 (4.4) | 0.424 |
| Antimalarials | ||||
| Chloroquine | 19 (8.7) | 15 (7.5) | 12 (5.8) | 0.938 |
| Hydroxychloroquine | 2 (0.9) | 2 (1) | 2 (1) | 1.00 |
| b/ts DMARDs | ||||
| Abatacep | 2 (0.9) | 3 (1.5) | 3 (1.5) | 0.824 |
| Adalimumab | 5 (2.3) | 5 (2.5) | 5 (2.4) | 1.00 |
| Certolizumab | 22 (10.1) | 17 (8.5) | 18 (8.7) | 0.827 |
| Etanercep | 15 (6.9) | 14 (7) | 13 (6.3) | 0.959 |
| Golimumab | 12 (5.5) | 11 (5.5) | 12 (5.8) | 0.985 |
| Infliximab | 5 (2.3) | 5 (2.5) | 4 (1.9) | 0.945 |
| Rituximab | 3 (1.4) | 2 (1) | 4 (1.9) | 0.776 |
| Tocilizumab | 9 (4.1) | 9 (4.5) | 9 (4.4) | 0.984 |
| Tofacinib | 6 (2.8) | 7 (3.5) | 7 (3.4) | 0.896 |
| csDMARDS | ||||
| Azathioprine | 4 (1.8) | 4 (2) | 3 (1.5) | 0.915 |
| Leflunomide | 113 (51.8) | 104 (51.7) | 100 (48.5) | 0.747 |
| Methotrexate | 127 (58.3) | 116 (57.5) | 96 (46.6) | 0.027 |
| Micofenolate | 0 (0) | 1 (0.5) | 1 (0.5) | 0.545 |
| Sulfasalazine | 36(16.5) | 30 (14.9) | 30 (14.6) | 0.834 |
| GCs | ||||
| Betamethasone | 22 (10.1) | 16 (8) | 11 (5.3) | 0.189 |
| Deflazacort | 10 (4.6) | 11 (5.5) | 12 (5.8) | 0.841 |
| Methylprednisolone | 2 (0.9) | 2 (1) | 2 (1) | 1.00 |
| Prednisone | 131 (60.1) | 123 (61.2) | 107 (51.9) | 0.116 |
Changes in the whole group in clinical outcomes and medications during follow-up. * Statistical differences were determined to be significant at p-values less than 0.05. ASAS-R: The Appraisal of Self-Care Agency Scale-Revised; b/ts DMARDs: biological/targeted synthetic disease-modifying antirheumatic drugs; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; DAS28: 28-joint Disease Activity Score; EQ5-overall index: EuroQol5 overall index values; EQ5-TTO: EuroQol5 time trade-off; EQ5-VAS: EuroQol5 visual analogue scales; GCs: glucocorticoids; HAQ: health assessment questionnaire disability index; IQR: interquartile range; PAS: patient activity scale; PGA: patient global assessment; VAS: visual analogue scale.